Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valbiotis SA ( (FR:ALVAL) ) just unveiled an update.
Valbiotis SA has transitioned from an R&D-focused company to a commercial enterprise, successfully launching its first product, Valbiotis®PRO Cholesterol, in France. The company has confirmed its strategic and financial goals through 2030, aiming for significant revenue growth and international expansion, supported by a strong product portfolio and strengthened governance.
More about Valbiotis SA
Valbiotis SA is a French laboratory specializing in the commercialization of scientifically validated dietary supplements aimed at preventing metabolic and cardiovascular diseases and promoting optimal daily health.
YTD Price Performance: -8.02%
Average Trading Volume: 1,502
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €20.3M
See more insights into ALVAL stock on TipRanks’ Stock Analysis page.